Quick search:
| Result | Content | Outlet | Published | Research |
|---|---|---|---|---|
| Result | Content | Outlet | Published | Research |
| 1 | New genetic clues on multiple sclerosis risk | Science Daily | 13 hours ago | |
| 2 | Quanterix' Simoa® Technology Powers Latest Breakthrough in Epstein-Barr Virus and Multiple Sclerosis | Business Wire | 3 days ago | |
| 3 | AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM) | Yahoo Finance | 26 days ago | |
| 4 | Janssen Showcases Recent Data in Relapsing Multiple Sclerosis at the 2021 European Committee for Treatment and Research in Multiple Sclerosis Congress | PRNewswire | 4 months ago | |
| 5 | Updated MS Guidelines Advocate Earlier, More Aggressive Treatment | Medscape | 3 months ago | |
| 6 | TG Therapeutics Announces Data for Ublituximab in Multiple | GlobeNewswire | 4 months ago | |
| 7 | Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | GlobeNewswire | 4 months ago | |
| 8 | #ECTRIMS2021 – Real-world Data Support Mavenclad for Relapsing MS | Multiple Sclerosis News Today | 4 months ago | |
| 9 | #ECTRIMS2021 – Quitting Smoking May Help Slow MS Progression | Multiple Sclerosis News Today | 4 months ago | |
| 10 | Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis | Yahoo Finance | 4 months ago | |
| 11 | #ECTRIMS2021 – For MS Disabilty, Ublituximab Is Better Than Aubagio | Multiple Sclerosis News Today | 3 months ago | |
| 12 | Agreement of different OCT scan directions for individual retinal-layer thickness measurements in multiple sclerosis subjects with prior unilateral optic neuritis | Scientific Reports | Nature.com | 17 days ago | |
| 13 | Looking Beyond the Typical Measures of MS Diagnosis | Medscape | 3 months ago | |
| 14 | Neurology Today | LWW Journals | 3 months ago | |
| 15 | #ECTRIMS2021 | ATA188 Benefits in SPMS, PPMS Hint at Remyelination | 4 months ago | |
| 16 | The News That Mattered in 2021: Neurology Today: Editorial... : Neurology Today | LWW Journals | 9 days ago | |
| 17 | Serum Neurofilament Light Level May Predict MS Progression | Medscape | 3 months ago | |
| 18 | ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis leadership | FiercePharma | 4 months ago | |
| 19 | Sanofi tries to quiet naysayers with follow-up data on MS drug at heart of $3.7B Principia buyout | FierceBiotech | 4 months ago | |
| 20 | Weed my lips: The good and not-so-good aspects of cannabis use among patients, part 2 | RDH Magazine | 10 days ago | |
| 21 | Gene therapy of prostate cancer using liposomes containing perforin expression vector driven by the promoter of prostate-specific antigen gene | Scientific Reports | Nature.com | 2 days ago | |
| 22 | Teprotumumab Proves Efficacious for Proptosis in Thyroid Eye Disease | Neurology Advisor | 2 months ago | |
| 23 | Which Agent Best for Neuromyelitis Optica? | Medscape | 3 months ago | |
| 24 | Virtual Care May Help Multiple Sclerosis Patients Even After the Pandemic | MedPage Today | 4 months ago | |
| 25 | Stem Cell Transplant Benefits in Secondary Progressive MS | Medscape | 3 months ago | |
| 26 | 2022 Orphan diseases outlook | The Pharma Letter | 4 days ago | |
| 27 | Ofatumumab Safety Data Reinforced By Multi-Year Study in Patients With Relapsing Multiple Sclerosis | Pharmacy Times | 3 months ago | |
| 28 | Frequent MRI May Spot Active Secondary Progressive MS More Quickly | MedPage Today | 3 months ago | |
| 29 | What's good for the heart is good for the brain | Science Daily | 3 days ago | |
| 30 | Year in Review: Multiple Sclerosis | MedPage Today | MedPage Today | 2 months ago | |
| 31 | Clene Nanomedicine Presents Blinded Interim Update from | GlobeNewswire | 4 months ago | |
| 32 | Biogen to face investors at JP Morgan healthcare conference | Triangle Business Journal | 23 days ago | |
| 33 | Diroximel Fumarate (Vumerity) Cleared for MS in Europe | Medscape | 2 months ago | |
| 34 | European Commission approves PONVORYTM (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features | Business Wire | 8 months ago | |
| 35 | Rituximab More Effective Than Other MS Treatments? | Medscape | 4 months ago | |
| 36 | The Pharma Letter Podcast — Episode 6 — Patient empowerment and multiple sclerosis | The Pharma Letter | 3 months ago | |
| 37 | Positive safety data for long-term use of MS drug Kesimpta | - pharmaphorum | 4 months ago | |
| 38 | Enspryng reduces relapse in NMOSD subgroup | Healio | 4 months ago | |
| 39 | CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial | Multiple Sclerosis News Today | 6 months ago | |
| 40 | The Latest on Multiple Sclerosis and COVID-19 Vaccines | Medscape | 4 months ago | |
| 41 | Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress | BioSpace | 3 months ago | |
| 42 | Amylyx Pharmaceuticals: Targeting Multiple Destructive Pathways To Reduce Neuronal Death | Seeking Alpha | 26 days ago | |
| 43 | Atara Biotherapeutics: Developing personalized, off-the-shelf therapies for multiple sclerosis | BioPharma-Reporter.com | 5 months ago | |
| 44 | BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS | PRNewswire | 4 months ago | |
| 45 | ECTRIMS-ACTRIMS 2017 | Medscape | 4 years ago | |
| 46 | New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis | Yahoo Finance | 4 months ago | |
| 47 | CHMP Recommends VUMERITY® (diroximel fumarate) for Approval | GlobeNewswire | 4 months ago | |
| 48 | TG Therapeutics Provides Business Update and Reports Third | GlobeNewswire | 3 months ago | |
| 49 | MS News That Caught My Eye Last Week: Deep Brain Stimulation... | Multiple Sclerosis News Today | 4 months ago | |
| 50 | Republicans Give Kristi Noem's Weird 'School Prayer Bill' a Big Nope | Daily Beast | 8 days ago | |
| 51 | European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm | Labiotech.eu | 2 years ago | |
| 52 | Thursday, January 27, 2022 | Kaiser Health News | 2 days ago | |
| 53 | COVID-19 Risks No Higher in Patients With Multiple Sclerosis | Medscape | 1 year ago | |
| 54 | Nanocrystals Boost Bioenergetics and Restore Neuronal Health | Genetic Engineering & Biotechnology News | 3 months ago | |
| 55 | The Spectrum of Multiple Sclerosis will be the focus at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum | Newswise | 1 year ago | |
| 56 | More Results for Ozanimod: DAYBREAK Data, Cognition and Gray Matter, Biomarker for Relapsing MS | AJMC.com Managed Markets Network | 2 years ago | |
| 57 | Ublituximab Under Review for Relapsing Forms of Multiple Sclerosis | Monthly Prescribing Reference | 2 months ago | |
| 58 | Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use | FiercePharma | 11 months ago | |
| 59 | Rituximab Better Than Natalizumab for MS Relapses? | Medscape | 2 months ago | |
| 60 | New Consensus Guideline on Clinical MRI Use in MS | Medscape | 3 months ago | |
| 61 | Efficacy of Ofatumumab Greater than Teriflunomide in Early Relapsing MS | Neurology Advisor | 1 year ago | |
| 62 | Ponesimod Shown Promising for MRI Outcomes in Relapsing MS | Neurology Advisor | 1 year ago | |
| 63 | BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update | PRNewswire | 3 months ago | |
| 64 | Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021 | PRNewswire | 11 months ago | |
| 65 | Novartis receives positive CHMP opinion for Kesimpta®* | GlobeNewswire | 1 year ago | |
| 66 | Cannabis Use Common for MS-Related Spasticity | Medscape | 3 months ago | |
| 67 | MS Therapy Fampyra Not Eligible To Be Added to NHS for England: NICE | Multiple Sclerosis News Today | 1 month ago | |
| 68 | ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42% | FiercePharma | 2 years ago | |
| 69 | Euro Roundup: CHMP recommends drugs from Biogen and Roche, knocks back Pfizer filing | Regulatory Focus | 4 months ago | |
| 70 | Multiple sclerosis and the COVID-19 vaccine: Safety and more | Medical News Today | 5 months ago | |
| 71 | Lessons for Patients With MS and COVID-19 | Medscape | 1 year ago | |
| 72 | Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress | Business Wire | 6 months ago | |
| 73 | Determining SPMS as Biological Instead of Classification | Managed Healthcare Executive | 10 months ago | |
| 74 | iMSMS Findings Offer Insight Into Gut Microbiome Involvement in MS | Neurology Advisor | 1 year ago | |
| 75 | ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021 | GlobeNewswire | 3 months ago | |
| 76 | Rivka Galchen · Whack-a-Mole: Anti-Vax Sentiments · LRB 27 January 2022 | London Review of Books | 10 days ago | |
| 77 | Janssen Announces US FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions | PRNewswire | 11 months ago | |
| 78 | New Data Further Reinforce Genentech's Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis | BioSpace | 1 year ago | |
| 79 | SK channel activation alters peripheral metabolic pathways | JIR | Dove Medical Press | 7 days ago | |
| 80 | Need to Know: What Is Acthar Gel? | Multiple Sclerosis News Today | 2 years ago | |
| 81 | MS treatment a step closer after drug shown to repair nerve coating | The Guardian | 1 year ago | |
| 82 | MS Society of Canada Urges Consistent Access to COVID-19 Boosters | Multiple Sclerosis News Today | 2 months ago | |
| 83 | Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies | The Lancet | 4 months ago | |
| 84 | Need to Know: What Are ACTRIMS and ECTRIMS? | Multiple Sclerosis News Today | 3 years ago | |
| 85 | Sun Exposure Linked to Reduced Pediatric MS Risk | Medscape | 11 months ago | |
| 86 | New Biogen Data Presented at ACTRIMS-ECTRIMS Advance | GlobeNewswire | 1 year ago | |
| 87 | Link Between Lesion Location and Obstructive Sleep Apnea in Multiple Sclerosis | Neurology Advisor | 2 years ago | |
| 88 | Convalescent plasma futile as treatment for critically ill COVID-19 patients, study finds | Science Daily | 4 months ago | |
| 89 | Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel | Wiley | 6 months ago | |
| 90 | A Cheap Biotech Stock Tests a Novel Treatment for Multiple Sclerosis | Barron's | 2 years ago | |
| 91 | New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and | GlobeNewswire | 1 year ago | |
| 92 | Preferences for Multiple Sclerosis Treatments in the US | PPA | Dove Medical Press | 7 months ago | |
| 93 | The Apparent Slowing of Disability Progression in Multiple Sclerosis | Neurology Advisor | 2 years ago | |
| 94 | Safety Concern With Fingolimod to Ocrelizumab Switch in MS | Medscape | 1 year ago | |
| 95 | PONVORY (ponesimod) for the Treatment of Multiple Sclerosis | Clinical Trials Arena | 10 months ago | |
| 96 | Treatment Options Lacking in Primary Progressive Multiple Sclerosis | AJMC.com Managed Markets Network | 1 year ago | |
| 97 | Janssen sends off NDA for new multiple sclerosis drug ponesimod | FierceBiotech | 2 years ago | |
| 98 | Dr John Corboy on Research About Stopping Disease-Modifying Therapies for Multiple Sclerosis | AJMC.com Managed Markets Network | 1 year ago | |
| 99 | Research shows race is a factor in disparities of symptom prevalence and response to treatment in multiple sclerosis treatment | Newswise | 10 months ago | |
| 100 | Update on Regulatory Submission for Aducanumab in the European UnionBiogen to seek re-examination following CHMP negative opinion for aducanumab | BioSpace | 1 month ago |